Clinical trial

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

NCT00002106

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE2

Study timeline

Registry last updated2005-06-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

Ranitidine hydrochlorideDRUG · verified · RxNorm: ranitidine hydrochloride

Sponsors & collaborators

Glaxo Wellcomelead sponsor

Mapped research locations

HoustonTexas, United States1 DurhamNorth Carolina, United States1 Coral GablesFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00002106 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.